73 results
424B5
TCRX
Tscan Therapeutics Inc
17 Apr 24
Prospectus supplement for primary offering
9:58pm
DESCRIPTION OF PRE-FUNDED WARRANTS
S-18
MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR INVESTORS IN OUR COMMON STOCK AND PRE-FUNDED WARRANTS
S-20 … that were not existing stockholders.
Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
8-K
EX-1.1
TCRX
Tscan Therapeutics Inc
17 Apr 24
TScan Therapeutics Announces Launch of $125 million Proposed
6:25am
subsidiaries have filed all federal, state, local and foreign tax returns required to be filed through the date of this Agreement or have requested … statements of the Company), and no tax deficiency has been determined adversely to the Company or any of its subsidiaries which, singly or in the aggregate
8-K
EX-4.1
7kopn541s74m
17 Apr 24
TScan Therapeutics Announces Launch of $125 million Proposed
6:25am
424B5
s8gaftg068yxb0gw
16 Apr 24
Prospectus supplement for primary offering
5:21pm
DEFA14A
sgsgg0r
2 Jun 23
Additional proxy soliciting materials
4:05pm
8-K
EX-4.1
jgstkoxc
31 May 23
TScan Therapeutics Announces Launch of Proposed Public Offering
8:16am